# Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

> **NCT04180371** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BicycleTx Limited** · enrollment: 288 (estimated)

## Conditions studied

- Advanced Solid Tumor Historically Known for High EphA2 Expression
- Urothelial Cancer
- Ovarian Cancer
- Non-small Cell Lung Cancer
- Head and Neck Cancer
- Triple Negative Breast Cancer
- Gastric/Upper Gastrointestinal Cancer

## Interventions

- **DRUG:** BT5528
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04180371
- **Lead sponsor:** BicycleTx Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-07
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180371, "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04180371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*